MedTrace Logo

Anabolic Therapy in Postmenopausal Osteoporosis

NCT05010590 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-04-15

No results posted yet for this study

Summary

In this research study we want to learn more about the effect of two different FDA-approved medications in the treatment of osteoporosis.

Conditions

  • Postmenopausal Osteoporosis

Interventions

DRUG

Romosozumab

Monthly romosozumab

DRUG

Denosumab

Every 6 months denosumab

Sponsors & Collaborators

Principal Investigators

  • Benjamin Leder, MD · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-24
Primary Completion
2027-10-01
Completion
2027-11-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05010590 on ClinicalTrials.gov